Objective: To determine the incidence, outcome, and risk factors for postattenuation neurological signs (PANS) and seizures after attenuation of single congenital portosystemic shunts (CPSS) in dogs.
Results: Twenty-eight (11.1%) dogs developed PANS, including 12 (4.7%) dogs with seizures. Five (17.9%) dogs with PANS did not survive to discharge. Risk factors for PANS included the presence of hepatic encephalopathy (HE) immediately preoperatively (P 5 .038, odds ratio [OR] 2.704, CI 1.057-6.922) and increasing age (P < .001, OR 1.476, CI 1.223-1.780). Risk factors for seizures included the presence of HE immediately preoperatively (P 5 .048, OR 3.538, CI 1.013-12.363) and increasing age (P 5 .009, OR 1.364, CI 1.082-1.720). No association was found between the location of portosystemic shunts (extrahepatic and intrahepatic) and postoperative PANS (P 5 .532) or seizures (P 5 .620). Similarly, preemptive administration of levetiracetam did not influence the risk of PANS (P 5 .991) or seizures (P 5 .752).
Conclusion: Preoperative HE and older age in dogs with a CPSS increased the odds of developing PANS and seizures in our population. Preemptive administration of levetiracetam did not protect dogs against the development of PANS or seizures.
Clinical significance: Surgical attenuation of a single CPSS should not be excessively delayed, and surgeons should stabilize the clinical signs of HE before surgery to prevent postoperative PANS and seizures.
| I NT ROD UCTI ON
Postattenuation neurological signs (PANS) are a complication of the surgical management of congenital portosystemic shunts (CPSS) reported in up to 12% of dogs. [1] [2] [3] [4] [5] [6] [7] Signs vary from mild ataxia 2, 8 to generalized seizure activity. 5, 6, 9 PANS is a wellrecognized complication in dogs; however, the underlying etiology is unclear and may be linked to changes associated with hepatic encephalopathy (HE) prior to surgery. 6, 9 Dogs with CPSS often display signs of HE, a poorly understood syndrome of neurological signs caused by alterations of multiple factors, including ammonia and false neurotransmitters. [10] [11] [12] In dogs with CPSS, ammonia and inflammatory mediators predict the presence of HE, 13 and indicators of inflammation decrease after successful CPSS attenuation. 14 HE is commonly observed in man secondary to a variety of liver diseases, but the pathogenesis remains unclear. HE may cause chronic alterations in the central nervous system (CNS), [15] [16] [17] [18] [19] [20] and there is direct evidence of astrocyte alterations in the brains of dogs with CPSS. 10, 21 The CNS is believed to adapt to an abnormal metabolic environment preoperatively, and the sudden change caused by surgical attenuation favors an excitatory state. 2 Damage to the CNS as a result of chronic portosystemic shunting, coupled with a metabolic event post attenuation, could result in PANS. 6 PANS has been distinguished from HE, 1 occurring in spite of full attenuation of the CPSS at surgery. 22, 23 In one study, all animals with PANS had normal levels of ammonia, 24 whereas HE is commonly associated with hyperammonaemia. 13 Increasing age has been associated with PANS in some studies 2,6,9 but not in others. 25, 26 Conflicting evidence has been published regarding the causal relationship between extrahepatic shunts and predisposition to PANS, and the effect of the method or degree of shunt attenuation is unknown. 2, 4, 23, 25, 27 Another potential cause of PANS relates to changes in natraemia, which affects osmolality (Osm). Indeed, central pontine myelinolysis is one of the most severe causes of postoperative neurological signs in people undergoing orthotopic liver transplantation and is associated with rapid correction of hyponatraemia. 28 In addition, a reduction in Osm increases the risk of seizures in people and other animals. 19, 29 The effects of prophylactic antiseizure medications in the perioperative management of dogs with CPSS have been met with mixed results. Perioperative administration of levetiracetam seemed to reduce the incidence of postoperative seizures in one retrospective study. 3 In another study, the administration of phenobarbitone potentially reduced the severity but not the incidence of neurological dysfunction. 2 The objective of this study was to determine the incidence, outcome, and predisposing factors for PANS and seizures in dogs undergoing surgical attenuation of single CPSS. We hypothesized that age, the presence of HE presurgery, extrahepatic location of the shunt, and alterations in Osm postoperatively would be associated with the incidence of PANS and seizures. In addition, we hypothesized that perioperative administration of levetiracetam would not affect the incidence of PANS or seizures.
| MA TERI A LS AND M ETH ODS
The records of dogs that underwent surgical attenuation of a single congenital portosystemic shunt at our institution between February 2000 and July 2015 were reviewed. Diagnosis of a single CPSS was confirmed at surgery with a mesenteric portovenogram in all cases. 30 
| Data collection
Details recorded were signalment; bodyweight; duration of clinical signs related to a CPSS (neurological, urinary, and gastrointestinal); severity and duration of HE prior to surgery; response to medical treatment prior to surgery; presurgery serum albumin; preoperative and 24-hour postoperative plasma ammonia; perioperative levetiracetam; shunt type (intrahepatic or extrahepatic); method of attenuation and the degree of attenuation achieved; postoperative serum Osm at 3 time points; the nature, timing and outcome of any complications related to PANS; and the number of days of hospitalization. Ammonia was measured by using a Stasar III spectrophotometer (Gilford Instrument Laboratories, Oberlin, Ohio) or a Jenway 6310 spectrophotometer (Bibby Scientific Limited, Staffordshire, United Kingdom). Albumin was measured by using an ILab 600 clinical chemistry analyzer (Instrumentation Laboratory, Werfen, Warrington, United Kingdom).
Electrolytes, urea (BUN), and glucose (Glu) were measured by using a blood gas analyzer. Osm was calculated by the blood gas analyzer by using the following formula: Osm (mOsm/kg) 5 1. (Table 3) . Dogs underwent CPSS attenuation according to a standardized surgical protocol. 25, 30 The anesthesia protocol was at the discretion of the anesthetist. As previously reported, the decision to attenuate the CPSS partially or completely was made on the basis of portal pressure measured via mesenteric vein catheterization and visual assessment of the pancreas and intestinal tract for signs of portal hypertension. Dogs that could tolerate a complete attenuation were treated with a complete acute suture ligation and those that could not were treated either with a partial suture ligation or with a cellophane band. 30 
| Statistical analysis
Data were analyzed in SPSS Statistics 23.0.0 (IBM, Woking, United Kingdom). Data were assessed graphically for normality. Median and range are reported for nonnormally distributed variables. Categorical data are reported as percentages. The preoperative and postoperative levels of plasma ammonia were compared by using the Wilcoxon signed-rank test. Statistical significance was set P .05. Univariable binary logistic regression was performed by using each potential predictor variable (Tables 4-5) as an initial screening to identify possible risk factors for PANS and seizures for use in multivariable models. Variables were selected for univariable binary logistic regression that had been previously associated with outcome or were related to the study hypothesis. 2, 3, 6, 13, 19, 32 Multivariable binary logistic regression models were then developed initially by using the variables with a P value .10 in the univariable analysis. Variables were sequentially entered into the logistic regression model and retained if P .05. After the model was finalized, excluded variables were reassessed by individually reentering them back into the model. Two models were created, 1 for PANS and 1 for seizures. Correlation between variables used in the multivariable analysis was assessed by using a Spearman's rank correlation.
| RES U LTS
Two hundred fifty-three dogs with a single CPSS were included in the study. Three other cases were omitted because of incomplete medical records. When dogs had more than 1 surgery, only the details of the first surgery were included. One hundred thirty-seven (54.2%) dogs were male, and 116 (45.8%) dogs were female. One hundred seventyfive (69.2%) dogs were intact, and 78 (30.8%) dogs were neutered. Median age at time of surgery was 0.87 years .620
Degree of attenuation, n (%)
Complete 98 (40.7)
Complete 7 (58.3)
.234
Partial 143 (59. Twelve (4.74%) dogs did not survive to discharge; 7 of these dogs died or were euthanized for reasons not related to PANS. Three dogs died or were euthanized due to severe gastrointestinal hemorrhage, 1 dog died due to suspected portal hypertension and pulmonary thromboembolism, 1 dog died due to severe anemia secondary to a coagulopathy, 1 dog died due to a portal vein thrombus, and 1 dog died due to postoperative intussusception. Twenty-eight (11.1%) dogs developed PANS ( 
| Univariable analysis
The univariable binary logistic regression identified several variables with a P value <.10 as presented in Tables 4 and 5 .
| Multivariable analysis
The final model of risk factors for PANS included increasing age (P < . Increasing age correlated with Osm 1 (P < .001, R 5 0.349), Osm 2 (P < .001, R 5 0.387), Osm 3 (P < .001, R 5 0.563), and duration of clinical signs (P < .001, R 5 0.401) and correlated negatively with postoperative ammonia (P 5 .005, R 5 0.255). Duration of clinical signs correlated with the duration of medical management (P < .001, R 5 0.311).
| D IS C US S I ON
Although PANS do not occur frequently (11.1% in this study), they are a major cause of mortality in dogs recovering from surgical attenuation of CPSS. The unknown etiology prevents treatment of underlying causes. Instead, symptomatic treatment relies on antiseizure medication to control neurological signs. Severe PANS may be refractory to such measures, as reflected in a high mortality rate of 20%-100%. 2, [5] [6] [7] 24, 33, 34 PANS may be triggered by a change in the CNS environment after anesthesia and surgery, compounding prior exposure of astrocytes to 1 or more substances implicated in the pathogenesis of HE. 6, 9 In this study, the presence of HE immediately preoperatively and age were independent risk factors for the development of PANS after surgical attenuation of a single CPSS. The odds of PANS increased 1.476-fold with each year of age in our population. The presence of HE immediately before surgery increased the odds of PANS 2.704-fold. Older dogs have been exposed for a longer time to alterations within the CNS. Chronic or irreversible astrocyte damage by 1 or more neurotoxic substances has been proposed as a trigger for the development of neurological abnormalities when dogs are challenged by an anesthetic and surgical procedure. Our results are consistent with previously published reports suggesting that older dogs are predisposed to postoperative complications, neurological or otherwise. 2, 6, 7, 9, 23, 35 In a previous study, Greenhalgh et al 36 suggested that age at diagnosis was not associated with long-term survival, and they concluded that there was no indication that surgical intervention should be performed early in life to be beneficial. However, the results of the current study would suggest that delaying surgery could increase the risk of PANS. Dogs with signs of HE immediately prior to surgery either responded poorly to medical therapy or had not received medical therapy. CNS alterations may have been more severe, or the lack of medical therapy contributed to an unstable neurological state, resulting in a larger relative change in the CNS environment following shunt attenuation. The findings of the current study support the notion that alterations in the CNS preoperatively are implicated in the neurological dysfunction seen postattenuation. Our results are in agreement with a previous study in which dogs without preoperative HE had fewer complications after CPSS attenuation compared with dogs with preoperative HE. 37 However, our results are contrary to the results of another study that concluded that the presence of HE preoperatively did not affect the likelihood of the development of PANS or seizure activity. 2 Authors of other studies have not been able to draw any conclusions regarding the importance of preoperative HE in the development of PANS. 3, 9 The reasons for discrepancies between studies are likely to include sample size, the retrospective nature of the studies, and the lack of clarification of timing of observation of HE. The improvement of HE with medical management makes this information critical. The separation of the clinical signs of preoperative HE and postoperative PANS can be difficult, particularly in dogs that have undergone partial shunt attenuation. In this study, among the 28 dogs with PANS, 9 showed clinical signs of HE immediately preoperatively. Paired (preoperative and postoperative) ammonia samples in 3 of the dogs affected by PANS showed a marked reduction in ammonia, lending evidence to 2 distinct neurological syndromes and not simply a continuation of HE. Hyperammonemia is a common finding in dogs with HE. However, serum ammonia levels in dogs decrease after CPSS attenuation, including in dogs with PANS. 13, 24, 34 The conversion of ammonia to glutamine within the astrocyte is considered to be a factor in HE, resulting in osmotic stress and energy depletion. 16, 38 However, the severity of neurological signs does not always correlate with hyperammonemia, and serum levels of ammonia can be normal in dogs, cats, and man with HE, suggesting the involvement of other pathways. 13, 39, 40 Preoperative ammonia levels were not associated with the development of PANS in this study, which is consistent with the complex pathogenesis of PANS. Several factors were not found to be predictive of PANS, conflicting with our hypotheses. Perioperative treatment with levetiracetam was instigated at our institution in 2012, subsequent to a report by Fryer et al 3 suggesting that perioperative medication with levetiracetam reduced the risk of postoperative seizures. Our results are inconsistent with the report by Fryer and colleagues in which only dogs with seizures were included. Although prophylactic levetiracetam did not reduce PANS or seizures in our study, it seemed to reduce mortality in severely affected cases. However, the cases of dogs receiving prophylactic levetiracetam were recent, and, therefore, reduced mortality could be result from increased experience treating PANS. The discrepancy between studies could also reflect variation in the dosage and the duration of treatment. These differences highlight the requirement for a prospective, controlled study to clarify the preventive value of perioperative antiseizure medication for PANS. The location of shunts (extrahepatic or intrahepatic) also failed to influence the development of PANS or seizure activity in this study. Our results conflict with those of a previous study in which dogs with extrahepatic shunts were predisposed to PANS, and seizure activity was compared with those with intrahepatic shunts. 2 In addition, the degree of attenuation that was achieved was not predictive of neurological dysfunction in the current study. In the univariable analysis, age, duration of the clinical signs, duration of medical management, and Osm at time points 2 and 3 were all significant, but, among these, only age proved to be a risk factor in the multivariable model. As expected, the duration of clinical signs correlated with age, and the duration of clinical signs correlated with the duration of medical management. The presence of preoperative HE was not significant in the univariable analysis but was a risk factor for PANS in the final model. There were also significant correlations between Osm and age. Osm, specifically sodium, has been implicated in the pathogenesis of HE in man, 16, 29, 41 contributing to the Alzheimer type II changes seen with astrocyte swelling. It is of special note that central pontine myelinolysis is associated with rapid correction of hyponatraemia, 28 and, therefore, increased Osm. In the current study, Osm was greater in dogs affected by PANS and seizures, which is worthy of additional study. Changes in postoperative Osm may be directly related to the occurrence of PANS but could also result from PANS. In addition, Osm may be related to age. The limitations of this study are inherent to its retrospective nature, with smaller subgroups for several important variables, particularly Osm. Although analysis of complications and behavioral changes used a detailed grading scale, retrospective analysis of these records is open to interpretation. Furthermore, information was collected over an extended period. Although this allows a large data set to be analyzed, it also introduces variability in the surgical, anesthetic, and medical management.
The identification of age and the presence of HE immediately preoperatively as risk factors for PANS and seizures prompt the authors to conclude that surgery should not be delayed for a prolonged period and that clinical signs of HE should be stabilized before surgery. Additional work is required to elucidate the underlying mechanism of PANS so that strategies can be targeted to improve treatment and prevent PANS. Although it will be difficult to enroll a sufficient number of dogs in a timely manner, a randomized, prospective study would be invaluable to determine the benefit of prophylactic antiseizure medications in dogs undergoing surgical management of CPSS.
